The RADAR-AD consortium recently published a paper which presents a review of the advice and opinions (i.e. qualification opinions, qualification advices and scientific advices) provided by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The authors conclude that, although there is a trend towards an increased use of remote monitoring technologies (RMTs) over time, their use in registration trials (a type of research study) is still relatively rare. This type of work can provide a better understanding of the EMA’s requirements regarding the use of RMTs in clinical trials for Alzheimer’s disease (AD). Most importantly, taking these recommendations into account could contribute towards a more optimal development of RMTs which are acceptable for regulatory agencies, and might also indirectly benefit people living with AD and their supporters/carers.
Read the full news story here.
